Computational design of a pentapeptide inhibitor for fibroblast growth factor receptor 3b (FGFR3b)

Fibroblast growth factor receptor (FGFR) is a cell membrane protein and a member of the tyrosine kinase family. It has extracellular domains that can be activated by ligand binding, followed by receptor dimerization. FGFR3 has 2 isoforms, 3b and 3c. The R248C mutation in FGFR3b leads to ligand independent receptor dimerization and results in different kinds of dermatological diseases such as seborrheic keratoses, acanthosis nigricans, and epidermal nevi. In order to prevent the increased cellular signaling caused by the R248C mutation, a pentapeptide ligand was designed that recognizes the mutation and binds to the receptor dimerization site. Molecular docking and steered molecular dynamics simulations were conducted, and binding free energy was calculated. The identified pentapeptide sequence appears to be a possible drug candidate for FGFR3b R248C mutation-related skin diseases.

Anahtar Kelimeler:

Key words: FGFR3b, peptide drug, binding free energy, steered molecular dynamics

Computational design of a pentapeptide inhibitor for fibroblast growth factor receptor 3b (FGFR3b)

Keywords:

Key words: FGFR3b, peptide drug, binding free energy, steered molecular dynamics,

PDF

___

Acree WE, Grubbs LM, Abraham MH (2012). Prediction of partition coefficients and permeability of drug molecules in biological systems with Abraham Model Solute Descriptors derived from measured solubilities and water to organic solvent partition coefficients. In: Acree B, editor. Toxicity and Drug Testing.
Akdoğan ED, Erman B, Yelekçi K (2011). In silico design of novel and highly selective lysine-specific histone demethylase inhibitors. Turk J Chem 35: 523–542.
Bernard-Pierrot I, Brams A, Dunoi s-Lardé C, Caillault A, Diez de Medina SG, Graff G, Thiery JP, Chopin D, Ricol D, Radvanyi F (2006). Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 27: 740–747.
Cuendet MA, Michielin O (2008). Protein-protein interaction investigated by steered molecular dynamics: the TCR-pMHC complex. Biophys J 95: 3575–3590.
Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG (1995). A smooth particle mesh Ewald method. J Chem Phys 103: 8577–8593.
Feller SE, Zhang YH, Pastor RW, Brooks BR (1995). Constantpressure molecular- dynamics simulation—the Langevin piston method. J Chem Phys 103: 4613–4621.
Fernandez-Fuentes N, Zhai J, Fiser A (2006). ArchPRED: a template based loop structure prediction server. Nucleic Acids Res 34: 173–176.
Froimowitz M (1993). Hyperchem(Tm)—a software package for computational chemistry and molecular modeling. Biotechniques 14: 1010–1013.
Gonnet P (2007). P-SHAKE: a quadratically convergent SHAKE in O(n(2)). J Comput Phys 220: 740–750.
Grater F, de Groot BL, Jiang H, Grubmuller H (2006). Ligand-release pathways in the pheromone-binding protein of Bombyx mori. Structure 14: 1567–1576.
Hafner C, Vogt T, Hartmann A (2006). FGFR3 mutations in benign skin tumors. Cell Cycle 5: 2723–2728.
Hafner C, Hartmann A, Van Oers JMM, Stoehr R, Zwarthoff EC, Hofstaedter F, Landthaler M, Vogt T (2007). FGFR3 mutations in seborrheic keratoses are already present in flat lesions and associated with age and localization. Modern Pathol 20: 895– 90
Hafner C, Hartmann A, Vogt T (2007). FGFR3 mutations in epidermal nevi and seborrheic keratoses: lessons from urothelium and skin. J Invest Dermatol 127: 1572–1573.
Hernández S, López-Knowles E, Lloreta J, Kogevinas M, Amorós A, Tardón A, Carrato A, Serra C, Malats N, Real FX (2006). Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 24: 3664–3671.
Humphrey W, Dalke A, Schulten K (1996). VMD: visual molecular dynamics. J Mol Graph Model 14: 33–38.
Isralewitz B, Baudry J, Gullingsrud J, Kosztin D, Schulten K (2001). Steered molecular dynamics investigations of protein function. J Mol Graph Model 19: 13–25.
Jorgensen WL (1981). Quantum and statistical mechanical studies of liquids transferable intermolecular potential functions for water, alcohols, and ethers—application to liquid water. J Am Chem Soc 103: 335–340.
Kale L, Skeel R, Bhandarkar M, Brunner R, Gursoy A, Krawetz N, Phillips J, Shinozaki A, Varadarajan K, Schulten K (1999). NAMD2: greater scalability for parallel molecular dynamics. J Comput Phys 151: 283–312.
Kitchen DB, Decornez H, Furr JR, Bajorath J (2004). Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 3: 935–949.
Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE (1982). A geometric approach to macromolecule-ligand interactions. J Mol Biol 161: 269–288.
Li W, Shen J, Liu G, Tang Y, Hoshino T (2011). Exploring coumarin egress channels in human cytochrome P450 2A6 by random acceleration and steered molecular dynamics simulations. Proteins 79: 271–281.
Logié A, Dunois-Lardé C, Rosty C, Levrel O, Blanche M, Ribeiro A, Gasc JM, Jorcano J, Werner S, Sastre-Garau X et al. (2005). Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet 14: 1153–1160.
Lu YJ, Yang J, Sega E (2006). Issues related to targeted delivery of proteins and peptides. Aaps J 8: 466–478.
L’Hote CG, Knowles MA (2005). Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 304: 417– 4
MacKerell AD, Bashford D, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D et al. (1998). All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102: 3586–3616.
Martyna GJ, Tobias DJ, Klein M (1994). Constant-pressure molecular-dynamics algorithms. J Chem Phys 101: 4177–4189. Mohammadi M, Olsen SK, Ibrahimi OA (2005). Structural basis for fibroblast growth factor receptor activation. Cytokine Growth F R 16: 107–137.
Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998). Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comp Chem 19: 1639–1662.
Naski MC, Wang Q, Xu J, Ornitz DM (1996). Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 13: 233–237.
Powers CJ, McLeskey SW, Wellstein A (2000). Fibroblast growth factors, their receptors and signaling. Endocr-Relat Cancer 7: 165–197.
Qing J, Du X, Chen Y, Chan P, Li H, Wu P, Marsters S, Stawicki S, Tien J, Totpal K et al. (2009). Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 119: 1216–1229.
Schlenkrich MJB, MacKerell AD, Karplus M (1996). An empirical potential energy function for phospholipids: criteria for parameter optimization and applications. In: Merz KM, Roux B, editors. Biological Membranes: A Molecular Perspective from Computation and Experiment. Boston, MA, USA: Birkhauser, pp. 31–81.
Scotet E, Houssaint E (1995). The choice between alternative 3b and 3c exons of the FGFR-3 gene is not strictly tissue-specific. Biochim Biophys Acta 1264: 238–242.
Tekin A, Yurtsever M (2002). Molecular dynamics simulation of phase transitions in binary LJ clusters. Turk J Chem 26: 627– 6
Toll A, Real FX (2008). Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next? Cell Cycle 7: 2674–2681.
Trott O, Olson AJ (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31: 455– 4
Trudel S, Ely S, Farooqi Y, Affer M, Robbiani DF, Chesi M, Bergsagel PL (2004). Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 103: 3521–3528.
Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK (2005). CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105: 2941–2948.